2023-11-01 2024-10-31 true No description of principal activity Capium Accounts Production 1.1 14400120 2023-11-01 2024-10-31 14400120 bus:FullAccounts 2023-11-01 2024-10-31 14400120 bus:FRS102 2023-11-01 2024-10-31 14400120 bus:AuditExemptWithAccountantsReport 2023-11-01 2024-10-31 14400120 bus:SmallCompaniesRegimeForAccounts 2023-11-01 2024-10-31 14400120 bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 14400120 2023-11-01 2024-10-31 14400120 2024-10-31 14400120 bus:RegisteredOffice 2023-11-01 2024-10-31 14400120 core:WithinOneYear 2024-10-31 14400120 core:AfterOneYear 2024-10-31 14400120 1 2023-11-01 2024-10-31 14400120 bus:Director1 2023-11-01 2024-10-31 14400120 bus:Director1 2024-10-31 14400120 bus:Director1 2022-10-05 2023-10-31 14400120 2022-10-05 14400120 bus:LeadAgentIfApplicable 2023-11-01 2024-10-31 14400120 2022-10-05 2023-10-31 14400120 2023-10-31 14400120 core:WithinOneYear 2023-10-31 14400120 core:AfterOneYear 2023-10-31 14400120 bus:EntityAccountantsOrAuditors 2022-10-05 2023-10-31 14400120 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 14400120 core:CostValuation core:Non-currentFinancialInstruments 2023-10-31 14400120 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-10-31 14400120 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 14400120 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 14400120 core:Non-currentFinancialInstruments 2024-10-31 14400120 core:Non-currentFinancialInstruments 2023-10-31 14400120 core:ShareCapital 2024-10-31 14400120 core:ShareCapital 2023-10-31 14400120 core:ShareCapitalOrdinaryShares 2023-11-01 14400120 core:ShareCapitalOrdinaryShares 2022-10-05 14400120 core:ShareCapitalOrdinaryShares 2023-11-01 2024-10-31 14400120 core:ShareCapitalOrdinaryShares 2022-10-05 2023-10-31 14400120 core:ShareCapitalOrdinaryShares 2024-10-31 14400120 core:ShareCapitalOrdinaryShares 2023-10-31 14400120 core:RetainedEarningsAccumulatedLosses 2023-11-01 14400120 core:RetainedEarningsAccumulatedLosses 2022-10-05 14400120 core:RetainedEarningsAccumulatedLosses 2023-11-01 2024-10-31 14400120 core:RetainedEarningsAccumulatedLosses 2022-10-05 2023-10-31 14400120 core:RetainedEarningsAccumulatedLosses 2024-10-31 14400120 core:RetainedEarningsAccumulatedLosses 2023-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14400120
England and Wales

 

 

 

MEDEXIFY LTD



Dormant Accounts
 


Period of accounts

Start date: 01 November 2023

End date: 31 October 2024
Director Ashraful Rana Islam
Registered Number 14400120
Registered Office 10B Bourne Court
Southend Road
London
England
IG8 8HD
Accountants EASTERN ACCOUNTANTS LTD
25 Cabot Square
Canary Wharf
London
E14 4QZ
1
The director presents his/her/their annual report and the financial statements for the year ended 31 October 2024.
The company is dormant and has not traded during the year.
Director

The director who served the company throughout the year was as follows:
Ashraful Rana Islam

On behalf of the board.


----------------------------------
Ashraful Rana Islam
Director

Date approved: 01 July 2025
2
Accountant’s report
You consider that the company is exempt from an audit for the year ended 31 October 2024 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
EASTERN ACCOUNTANTS LTD
31 October 2024



....................................................

EASTERN ACCOUNTANTS LTD

25 Cabot Square
Canary Wharf
London
E14 4QZ
01 July 2025
3

The company is dormant and has not traded during the year.

The company received no income and incurred no expenditure in the year and therefore made neither a profit nor loss.

The notes form part of these financial statements.

4
 
 
Notes
 
2024
£
  2023
£
Current assets      
Debtors 100    100 
Net current assets 100    100 
 
Total assets less current liabilities 100    100 
Net assets 100    100 
 

Capital and reserves
     
Called up share capital 100    100 
Shareholders' funds 100    100 
 


For the year ended 31 October 2024 the company was entitled to exemption from audit under Section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 01 July 2025 and were signed by:


-------------------------------
Ashraful Rana Islam
Director
5
  Equity share capital   Retained Earnings   Total
£ £ £
Total comprehensive income for the year
Shares issued 100  100 
Total investments by and distributions to owners 100  100 
At 31 October 2023 100  100 
At 01 November 2023 100  100 
Total comprehensive income for the year
Total investments by and distributions to owners
At 31 October 2024 100  100 
6
General Information
MEDEXIFY LTD is a private company, limited by shares, registered in England and Wales, registration number 14400120, registration address 10B Bourne Court, Southend Road, London, England, IG8 8HD.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
7